Ascentis Independent Advisors Has $4.76 Million Stake in Amgen Inc. $AMGN

Ascentis Independent Advisors boosted its position in Amgen Inc. (NASDAQ:AMGN) by 153.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,541 shares of the medical research company’s stock after acquiring an additional 8,192 shares during the quarter. Ascentis Independent Advisors’ holdings in Amgen were worth $4,765,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Anfield Capital Management LLC raised its holdings in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC boosted its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares in the last quarter. Board of the Pension Protection Fund acquired a new stake in Amgen in the fourth quarter valued at about $26,000. Tower View Wealth Management LLC grew its position in Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares during the last quarter. Finally, Manning & Napier Advisors LLC grew its position in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on AMGN shares. Mizuho increased their target price on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a report on Tuesday, June 16th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Daiwa Securities Group lowered their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Thursday, June 18th. Finally, Wells Fargo & Company upped their price target on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $355.50.

Amgen Price Performance

AMGN stock opened at $374.15 on Monday. The company has a market capitalization of $201.93 billion, a P/E ratio of 26.04, a PEG ratio of 3.68 and a beta of 0.41. The company has a fifty day moving average price of $342.43 and a 200-day moving average price of $348.09. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.39 EPS for the current year.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.